Alexandra Goodyear, MD, MS
Multiple sclerosis specialist
Other research interests include neuromyelitis optica, cost effectiveness and epidemiological research. Dr. Goodyear was awarded the Sylvia Lawry Clinical Trials Fellowship by the MS Society and completed a Masters in Epidemiology during her training. Dr. Goodyear completed her Neurology Residency at Stanford University Medical Center and served as Chief Resident. Dr. Goodyear attended Brown University for her undergraduate studies and began her medical career with two years of public health work in Senegal, West Africa as a Peace Corps Volunteer.
Medical Education: Tufts University (2007) MA
Fellowship: Stanford University School of Medicine (2013) CA
Board Certification: Neurology, American Board of Psychiatry and Neurology (2011)
Residency: Stanford University School of Medicine (2011) CA
Internship: Stanford University School of Medicine (2008) CA
MS Epidemiology, Stanford University School of Medicine, Department of Health Research and Policy, Epidemiology and Biostatistics (2013)
Resident in Neurology, Stanford University School of Medicine, Department of Neurology, Neurology (2011)
Internship in internal medicine, Stanford University School of Medicine, Internal Medicine (2008)
Honors & Awards
Chief Resident in Neurology, Stanford University School of Medicine, Department of Neurology (2010-2011)
SPARK Translational Science Research Grant, SPARK, Stanford School of Medicine (2013-2015)
Sylvia Lawry Physician Fellow in Clinical Trials, National Multiple Sclerosis Society (08/2011-08/2013)
Medical Director, Stanford Neurosciences Clinical Trials Group (2013 - Present)
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
A New Cost-effectiveness Microsimulation Model for Glatiramer Acetate and Dimethyl Fumarate.
Leeper, A., Owens, D., Goldhaber-Friebert, J., & Goodyear, A. (2013). A New Cost-effectiveness Microsimulation Model for Glatiramer Acetate and Dimethyl Fumarate. . Presented at the ECTRIMS.
Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein
Herges, K., de Jong, B. A., Kolkowitz, I., Dunn, C., Mandelbaum, G., & Axtell, R. C. (2012). Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. MULTIPLE SCLEROSIS JOURNAL, 18(4), 398-408.